Literature DB >> 7988179

Right ventricular dilatation, right ventricular wall thickening, and Doppler evidence of pulmonary hypertension in patients with a pure restrictive ventilatory impairment.

K Shivkumar1, K Ravi, J W Henry, M Eichenhorn, P D Stein.   

Abstract

The purpose of this investigation was to determine the severity of pure restrictive ventilatory impairment that results in right ventricular (RV) dilatation, increased RV wall thickness, and pulmonary hypertension. Two dimensional (2-D) echocardiography, Doppler measurements of pulmonary flow, and spirometry were performed on 26 unselected patients (17 female, 9 male) with a pure restrictive ventilatory impairment. A restrictive ventilatory impairment was defined as a forced vital capacity (FVC) < or = 80 percent predicted with a normal FEV1/FVC ratio (FEV1 = 1 s forced expiratory volume). The patients were grouped according to the severity of the restrictive ventilatory defect: mild (FVC, 65 to 80 percent predicted), moderate (FVC, 51 to 64 percent predicted), and severe (FVC < or = 50 percent predicted). An increased RV area (> 20.4 cm2) was shown in 0 of 10 (0 percent) patients with a mild impairment, 6 of 12 (50 percent) patients with moderate restriction, and 2 of 4 (50 percent) patients with severe restriction. Increased RV wall thickness (> 0.5 cm) was observed in 0 of 10 (0 percent) patients with mild restrictive impairment, 3 of 12 (25 percent) with moderate impairment, and 1 of 4 (25 percent) with severe restrictive impairment. Doppler evidence of pulmonary hypertension (ACT/ET ratio < 0.32) (ACT = acceleration time, ET = ejection time) was shown in 0 of 10 (0 percent) patients with a mild restrictive impairment, 8 of 12 (66 percent) patients with moderate restriction, and 4 of 4 (100 percent) patients with severe restriction (p < 0.01 mild vs moderate and mild vs severe). The RV area by 2-D echocardiography correlated well with the FVC percent predicted (r = 0.90, p < 0.001). The ACT/ET ratio also correlated well with the FVC percent predicted (r = 0.73, p < 0.001). In conclusion, RV enlargement and pulmonary hypertension were seen only in patients with a moderate or severe restrictive ventilatory impairment. These data may be useful in the assessment of the likelihood of subtle RV enlargement in patients with occupational pleuropulmonary disease.

Entities:  

Mesh:

Year:  1994        PMID: 7988179     DOI: 10.1378/chest.106.6.1649

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  6 in total

Review 1.  Right ventricular dysfunction in chronic lung disease.

Authors:  Todd M Kolb; Paul M Hassoun
Journal:  Cardiol Clin       Date:  2012-05       Impact factor: 2.213

Review 2.  Group 3 Pulmonary Hypertension: From Bench to Bedside.

Authors:  Navneet Singh; Peter Dorfmüller; Oksana A Shlobin; Corey E Ventetuolo
Journal:  Circ Res       Date:  2022-04-28       Impact factor: 23.213

3.  CT scanning in the evaluation of pulmonary hypertension.

Authors:  Jennifer C Kam; Justin Pi; Vikram Doraiswamy; Yaser Elnahar; Sami Abdul-Jawad; Vincent A DeBari; Alan J Klukowicz; Fayez Shamoon; Richard A Miller
Journal:  Lung       Date:  2013-05-29       Impact factor: 2.584

4.  Relationship of Right Ventricular Size and Function with Respiratory Status in Duchenne Muscular Dystrophy.

Authors:  Muddassir Mehmood; Stephanie A Ambach; Michael D Taylor; John L Jefferies; Subha V Raman; Robin J Taylor; Hemant Sawani; Jacob Mathew; Wojciech Mazur; Kan N Hor; Hussein R Al-Khalidi
Journal:  Pediatr Cardiol       Date:  2016-03-02       Impact factor: 1.655

Review 5.  Lung function and cardiovascular disease: A link.

Authors:  Sergio H R Ramalho; Amil M Shah
Journal:  Trends Cardiovasc Med       Date:  2020-01-03       Impact factor: 6.677

6.  Diagnostic Value of Selected Echocardiographic Variables to Identify Pulmonary Hypertension in Dogs with Myxomatous Mitral Valve Disease.

Authors:  A Tidholm; K Höglund; J Häggström; I Ljungvall
Journal:  J Vet Intern Med       Date:  2015-09-14       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.